Health Care: Biotechnology 2010 Third
Institutional Investor Research is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Health Care: Biotechnology 2010 Third

Geoffrey Porges of Sanford C. Bernstein & Co., who lands in third place for a third consecutive year, does “great contrarian valuation work,” declares one portfolio manager.

Geoffrey Porges Sanford C. Bernstein & Co.


Geoffrey Porges of Sanford C. Bernstein & Co., who lands in third place for a third consecutive year, does “great contrarian valuation work,” declares one portfolio manager. When many analysts concluded in July 2009 that shares of Rockville, Maryland–based Human Genome Sciences were fully valued at $12.51, Porges argued that the stock had plenty of room left to run. Boy, did it. The share price had catapulted 132.4 percent, to $29.07, by the end of August 2010.


Gift this article